Richard F. Little, M.D.

Dr. Richard F. Little came to NIH in 1992 and joined CTEP in 2007 as head of the therapeutics section for Hematologic and AIDS-related Cancers and Hematopoietic Stem Cell Transplant, focused on overseeing, reviewing, and coordinating the NCI-sponsored late phase cancer treatment trials in these diseases. Dr. Little led the development of MyeloMATCH, a portfolio of AML and MDS trials that uses advanced assays to target residual disease with increasing precision as newly diagnosed patients undergo treatment. 

In 2026, Dr. Little became a Physician Consultant with DCTD to support activities related to NCI extramural clinical trials, with an emphasis on hematologic malignancies.

Dr. Little received his medical degree from the University of South Carolina in 1989. After completing residency training in internal medicine at the Boston City Hospital, he completed a combined medical oncology and hematology fellowship in 1994 at the National Heart Lung and Blood Institute and the National Cancer Institute. Dr. Little was recognized as an outstanding teacher and mentor in 2005 when he was nominated for the Distinguished NIH Teacher award.